

(51) International Patent Classification:
C12N 15/01 (2006.01) *C12N 7/00* (2006.01)(21) International Application Number:
PCT/SG2010/000424(22) International Filing Date:
8 November 2010 (08.11.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
200907415-4 6 November 2009 (06.11.2009) SG(71) Applicants (for all designated States except US): **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis, Singapore 138632 (SG). **NANYANG TECHNOLOGICAL UNIVERSITY** [SG/SG]; 50 Nanyang Avenue, Singapore 639798 (SG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GHADESSY, Farid John** [GB/SG]; c/o Experimental Therapeutics Centre, 31 Biopolis Way, Nanos Level 3, Singapore 138669 (SG). **TAY, Mei Sian Yvonne** [SG/SG]; c/o Institute of Medical Biology, 8A Biomedical Grove, #06-06 Immunos, Singapore 138648 (SG). **DROGE, Peter** [DE/SG]; c/o School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551 (SG).(74) Agent: **VIERING, JENTSCHURA & PARTNER LLP**; P.O. Box 1088, Rochor Post Office, Rochor Road, Singapore 911833 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MUTEINS OF THE BACTERIOPHAGE LAMBDA INTEGRASES

Name	Total mutations	Mutations									
Int1	2		I43F	H61R							
Int2	6				R109G		E134G	A154V	A182T	G252L	I253L
Int3	2					K122R					C262R
Int4	2	E8K		H61R							
Int5	1		I43F								
Int6	2			H61R		K122R					

Table 1

Figure 10

(57) Abstract: The present invention refers to muteins of the bacteriophage lambda integrases and to nucleic acid molecules comprising a nucleotide sequence encoding such muteins of the lambda integrases. The invention further refers to host cells containing a nucleic acid molecule comprising a nucleotide sequence encoding such muteins of the lambda integrases. The invention also refers to methods of recombining nucleic acids of interest into target nucleic acids in the presence of the muteins of the lambda integrases, as well as sequence specific recombination kits.